The Chinese biotech said US regulators have cleared it to start trials of the therapy for patients with B-cell lymphoma.
The firm reported $11.4 million in net revenue from Zevaskyn for the three months ended June 30, missing analysts' expectations of roughly $12.3 million.
PMC's new president and CEO said the organization is expanding beyond oncology, engaging with Capitol Hill, and challenging a controversial research grant rule.
NEW YORK – Epicrispr Biotechnologies has raised $90 million in an oversubscribed Series C funding round to advance its pipeline of epigenetic medicines that regulate gene expression. The Series C ...
US regulators are already reviewing data from a later-line trial, but Taiho now says it could seek a first-line indication for the EGFR inhibitor.
The investigator-initiated trial comes after Elicio said a Phase II trial of ELI-002 7P in adjuvant pancreatic cancer did not meet its primary endpoint.
NEW YORK – Akeso Bio has launched a Phase II study of a bispecific antibody-drug conjugate in combination with its bispecific antibody ivonescimab for advanced breast cancer. The Zhongshan, ...
The firm disclosed the update on the gene therapy, which it acquired in its 2021 purchase of Prevail Therapeutics, in its Q2 ...
NEW YORK – The US Food and Drug Administration approved Laboratory Corporation of America's PGDx elio tissue complete as a companion diagnostic for detecting BRAF V600E and BRAF V600K mutations in ...
The deal centers on Actio's small molecule for KCNT1-related epilepsy. Meanwhile, Actio will spin out a separate company with its other assets.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results